Daily Chart: COVID-19 vaccines by phase and modality
Among the 157 COVID-19 vaccines in development, at least 18 have reached the clinic.
Sichuan Clover Biopharmaceuticals Inc. is the latest company to enter the clinic with a vaccine, announcing Friday that it had begun dosing the first volunteers in a Phase I trial of its COVID-19 candidate.
Protein-based vaccines, which include full-length viral proteins, peptide antigens and virus-like particles, make up the most common group.
Each vaccine modality comes with a different set of pros and cons and varying levels and durations of immunity (see “Guide to Preclinical Vaccine Modalities” and “Guide to Clinical Vaccine Modalities”).